PubMed Journals: Clin Exp Immunol
Source: PMID: 30993689
⇦ ⇨ Clin Exp Immunol. 2019 May;196(2):155-156.
⇩ doi: 10.1111/cei.13303.
Vaccines for emerging pathogens: from research
to the clinic.
(1) Defence Science and Technology Laboratory,
Porton Down, Salisbury, UK.
In this two-part series of reviews, we have
invited experts in their fields to contribute
articles on the status of vaccine research
and development for emerging pathogens. This
topic has been brought into sharp focus
in recent years following significant outbreaks
of viral diseases such as those causing
severe acute respiratory syndrome and
Middle East respiratory syndrome, as well
as devastating outbreaks of diseases caused by
the Ebola, Marburg, Zika and Lassa fever
viruses, to name only a few examples. Additionally,
bacterial infections leading to bubonic
and pneumonic plague, most notably in Madagascar
in 2018, as well as malaria in many tropical countries,
melioidosis in south east Asia and tularaemia
in northern Europe and North America, have
incurred significant morbidity and mortality.
In this review series, the life cycle of
these pathogens and the epidemiology of
disease have been reviewed in the context
of potential points of intervention for
the prevention of human infection. Many
of the emerging pathogens are zoonoses and,
as such, there is scope for intervention
at the animal/insect/environmental reservoir. Other pathogens
covered in this review series are considered
to be re-emerging, such as
multi-drug resistant tuberculosis.
© 2019 Crown copyright. Clinical and Experimental
Immunology © 2019 British Society for Immunology.
This article is published with the permission
of the Controller of HMSO and the Queen's
Printer for Scotland.
DOI: 10.1111/cei.13303 PMCID: PMC6468174